Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM. et al, (2015), Lancet Oncol, 16, 928 - 936
The effect of formalizing enhanced recovery after esophagectomy with a protocol.
Findlay JM. et al, (2015), Dis Esophagus, 28, 567 - 573
The effect of formalizing enhanced recovery after esophagectomy with a protocol
Findlay JM. et al, (2015), Diseases of the Esophagus, 28, 567 - 573
Early phase cancer clinical trials: design, ethics and future directions.
Coupe N. et al, (2015), Br J Hosp Med (Lond), 76, 409 - 413
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Mead AJ. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 170, 29 - 39
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ. et al, (2015), Br J Haematol, 170, 29 - 39
Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience.
Eyre TA. et al, (2015), Am J Hematol, 90, E103 - E110
Management and controversies of classical Hodgkin lymphoma in pregnancy.
Eyre TA. et al, (2015), Br J Haematol, 169, 613 - 630
PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR. et al, (2015), Womens Health (Lond), 11, 355 - 367
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas AL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
Olszanski AJ. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Van Schaeybroeck S. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Wainberg ZA. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark LL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).
Sims MC. et al, (2015), Br J Haematol, 169, 452 - 455
Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
Lord SR. et al, (2015), J Natl Cancer Inst Monogr, 2015, 81 - 86